BPC-157

What BPC-157 has been studied for

The reasons people look it up, roughly in order of how often, and what research exists for each. Interest in a use is not evidence that it works; the evidence is stated under each one.

Tendon and ligament injuries

The most common reason people look it up, and where the preclinical research is thickest. Tendons heal slowly because blood struggles to reach them, which is the specific problem the preclinical work describes BPC-157 addressing. No human tendon trial has been published.

Inflammation

Described in preclinical work as calming inflammation without shutting it down, which matters because some inflammation is part of healing. Not studied in people.

Gut irritation

The area with the longest research history, since the parent protein was found in stomach fluid. Includes preclinical work on damage caused by anti-inflammatory painkillers, and the one clinical trial, in ulcerative colitis, whose results were never published in full.

Recovery after injury or surgery

Muscle tears, post-operative healing, and injuries that have stalled. What exists is preclinical work plus anecdote, and anecdote is not evidence.

Joint pain

Usually knees. The human record is one retrospective chart review of 16 people with no control group (Lee and Padgett, 2021).

Nerve damage

A smaller and more preliminary body of preclinical work than the tendon research, looking at whether damaged nerve tissue recovers faster. Early, and worth treating as such.

Mechanism of Action

How BPC-157 works

BPC-157 side effects: what studies reported

There is no large trial to draw a formal side-effect table from, so what follows is the small human safety work plus reports collected outside trials. The largest documented risk is product quality rather than the molecule.

Source: Reported use plus the small human safety work; there is no large trial to draw a formal table from. This is a summary of published findings, not a complete safety profile and not medical advice. Questions about BPC-157 belong with a licensed clinician who knows your history.

The dots after each gene are where your own result goes. Your report fills them in with the two letters you carry at that position.

Often discussed alongside

Compounds that come up next to BPC-157 in research and discussion. Each has its own page. None of this is a suggestion to combine them.

TB-500

the Wolverine pairingEmerging Evidence

TB-500

TB-500 is a short seven-amino-acid fragment copied from the middle of a much larger protein your body makes called thymosin beta-4. That protein is 43 amino acids long and helps cells travel to the site of an injury; TB-500 is the small piece of it thought to do that job. The human trials used the full protein, not the fragment, and the name TB-500 is applied to both, which makes much of what is written about it ambiguous.

3

Gene variants

50+

Studies

GHK-Cu

tissue repair researchModerate Evidence

Glycyl-L-Histidyl-L-Lysine Copper Complex

A naturally occurring copper-binding tripeptide, studied mainly for wound healing and skin. It carries copper into tissue, where copper is the cofactor the enzyme that cross-links collagen cannot work without. Most of the evidence is topical or preclinical; the widely quoted gene-expression claims rest on far less than they appear to.

4

Gene variants

100+

Studies

KPV

gut researchEmerging Evidence

KPV (Lys-Pro-Val)

A three-amino-acid fragment snipped off the end of a hormone your body already makes. Almost every page describes it as switching on a melanocortin receptor; the research fairly clearly says it does not. What it appears to do instead is more interesting, and it is why nearly all the data are about the gut rather than skin. No human study of KPV has been published.

4

Gene variants

15+

Studies

Named combinations

A combination people search for by name, and what research exists on it.

Tissue repair research

Wolverine Stack

BPC-157 and TB-500: what the research does and does not show

BPC-157

TB-500

Access

Access and legal status

BPC-157 is not an FDA-approved drug. Products sold online as “research chemicals” are labelled not for human use, and FDA treats them as unapproved drugs when they are marketed for people. We don't link to any seller, and nothing on this page is a recommendation to obtain or use it.

Educational information only, not medical advice. Most peptides are not FDA-approved. Do not start, stop or change any medication or peptide because of this page; talk to a licensed clinician.

Worth knowing about BPC-157

Interactions and situations where there is a specific reason to be careful. Where the honest answer is that nobody has studied something, it says so and says what that leaves open.

Product quality is the largest documented risk

A 2026 analysis of 6,441 grey-market peptide samples found between 42% and 71% failed basic quality checks depending on the standard applied, and 15% carried measurable endotoxin. That is a larger and better-documented problem than anything known about the molecule itself.

Reported skin and gum darkening, with a combined product

The FDA's adverse-event system carries a report of diffuse skin hyperpigmentation and darkening of the gums in a woman using a BPC-157 and TB-500 product. It cleared when she stopped and returned when she restarted, which is strong for a single case. Because the product held two peptides, nobody can say which one caused it.

Anyone drug-tested in sport

BPC-157 is prohibited at all times under the non-approved substances category, not just in competition. It is banned outright.

Active or previous cancer

Much of what BPC-157 is described as doing involves growing new blood vessels, which is also how tumours establish a supply. Nothing shows it promotes cancer and nothing rules it out: no carcinogenicity study has been done. That absence is the reason to raise it with an oncologist rather than decide alone.

Pregnancy and breastfeeding

Never studied, in humans or in preclinical models. There is no basis for judging risk in either direction.

Other medicines

No drug-interaction study exists. Worth knowing specifically about anti-inflammatory painkillers: BPC-157's gut research is largely about damage those drugs cause, and that combination has only been looked at in preclinical models.

Frequently Asked Questions